

YOUR MEDICAL ISOTOPES PARTNER

Ontario is where the future of medical isotope production is being redefined. As a global leader in nuclear science and innovation, our province has been at the forefront since the first sustained nuclear chain reaction outside the United States. Today, Ontario continues to drive progress in nuclear medicine, producing life-saving isotopes that support cancer treatment, diagnostics, and sterilization around the world. These isotopes are deeply embedded within our thriving life sciences ecosystem—powering breakthroughs in cancer care, pharmaceuticals, and medical technologies.

Our reactors are also advancing the production of yttrium-90, lutetium-177, and molybdenum-99, supporting the next generation of radiotherapies. Ontario's power reactors and nuclear research facilities are not only producing isotopes that can treat thousands of cancer patients annually, but also pushing the boundaries of what nuclear medicine can achieve. Backed by a highly skilled workforce and a legacy of innovation, Ontario offers an unparalleled environment for businesses and researchers to lead the next era of medical isotope development—where cutting-edge science meets a robust and collaborative health innovation network.

ONTARIO'S MEDICAL ISOTOPES INDUSTRY BY THE NUMBERS

3
OF FOUR CANADIAN
RESEARCH REACTORS

70,000+
STEM GRADUATES
ANNUALLY

16 CANDU REACTORS IN
ONTARIO ACROSS 3 NUCLEAR
POWER STATIONS – BRUCE,
DARLINGTON, AND PICKERING

#1
SUPPLIER OF
HOLMIUM-166

65,000
JOBS SUPPORTED IN
THE NUCLEAR SECTOR

OVER **50%**
OF THE GLOBAL SUPPLY
OF COBALT-60

ONTARIO ISOTOPES EXPERTISE AND LEADERSHIP IN:

- Actinium-225
- Carbon-14
- Cobalt-60
- Helium-3
- Holmium-166
- Iodine-125
- Lutetium-177
- Molybdenum-99
- Yttrium-90

DRIVING NEXT GENERATION **MEDICAL ISOTOPE PRODUCTION**

Ontario has launched the Nuclear Isotope Innovation Council of Ontario (NIICO) to collaborate with the Canadian Nuclear Isotope Council, health care experts, and industry leaders to leverage the province's world-class nuclear fleet. By aligning the Life Sciences Strategy with Ontario's integrated energy plan, the province will double medical isotope production by 2030—expanding life-saving treatment options for head, neck, liver, and cervical cancers and reinforcing Ontario's position as a global biomanufacturing and innovation hub.

THE TOP 5 REASONS TO **CHOOSE ONTARIO**

1. TALENT

74% of working adults possess a post-secondary education



2. INNOVATION ECOSYSTEM

Business, academia and government work together to drive bold ideas to market

3. COMPETITIVE COSTS

Some of the lowest corporate taxes in North America

Save up to 50% on after-tax R&D expenditures

Source high quality products and services that are extremely cost-competitive



4. ACCESS TO GLOBAL MARKETS


A short distance to U.S. hubs

15 free trade agreements with 51 countries

5. DIVERSITY

People from 150 countries

Over 200 languages spoken



Ontario's leadership in medical isotopes is a powerful example of how the nuclear supply chain supports both economic growth and global health."

Ivette Vera-Perez
President and CEO
Organization of Canadian Nuclear Industries

RESEARCH LIVES HERE

Ontario is a world leader in research and innovation. McMaster Nuclear Reactor is the most powerful research reactor in the country, providing the only major neutron source. With the ability to produce hundreds of doses weekly of Iodine-125, over 70,000 patients globally are able to be treated. This dedication to excellence is preparing for the future for medical innovation.

FOR MORE INFORMATION ABOUT ONTARIO'S LIFE SCIENCE SECTOR:

SourceFromOntario.com | InvestOntario.ca

Ontario

All figures are in Canadian dollars unless otherwise noted.
This information is accurate at the time of printing.

© King's Printer for Ontario, 2025 ENG/09/25
Printed in Ontario, Canada.